X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs STERLING BIOTECH - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD STERLING BIOTECH STRIDES SHASUN LTD/
STERLING BIOTECH
 
P/E (TTM) x 41.4 -0.3 - View Chart
P/BV x 1.0 0.0 7,610.4% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 STRIDES SHASUN LTD   STERLING BIOTECH
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
STERLING BIOTECH
Dec-13
STRIDES SHASUN LTD/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,27511 12,140.0%   
Low Rs9183 27,000.0%   
Sales per share (Unadj.) Rs389.626.8 1,453.2%  
Earnings per share (Unadj.) Rs28.0-15.0 -187.0%  
Cash flow per share (Unadj.) Rs48.9-5.5 -895.1%  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs303.154.9 552.3%  
Shares outstanding (eoy) m89.42267.87 33.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 1,085.5%   
Avg P/E ratio x39.2-0.5 -8,436.1%  
P/CF ratio (eoy) x22.4-1.3 -1,762.3%  
Price / Book Value ratio x3.60.1 2,856.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m98,0361,862 5,265.9%   
No. of employees `0005.81.4 428.4%   
Total wages/salary Rs m5,881547 1,075.6%   
Avg. sales/employee Rs Th6,005.95,303.3 113.2%   
Avg. wages/employee Rs Th1,014.0403.8 251.1%   
Avg. net profit/employee Rs Th431.2-2,959.0 -14.6%   
INCOME DATA
Net Sales Rs m34,8347,181 485.1%  
Other income Rs m1,68643 3,957.3%   
Total revenues Rs m36,5207,223 505.6%   
Gross profit Rs m6,428947 678.8%  
Depreciation Rs m1,8722,543 73.6%   
Interest Rs m2,2694,377 51.8%   
Profit before tax Rs m3,973-5,931 -67.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,0060-   
Tax Rs m470-1,924 -24.4%   
Profit after tax Rs m2,501-4,007 -62.4%  
Gross profit margin %18.513.2 139.9%  
Effective tax rate %11.832.4 36.5%   
Net profit margin %7.2-55.8 -12.9%  
BALANCE SHEET DATA
Current assets Rs m38,16514,335 266.2%   
Current liabilities Rs m30,40249,809 61.0%   
Net working cap to sales %22.3-494.0 -4.5%  
Current ratio x1.30.3 436.2%  
Inventory Days Days77403 19.2%  
Debtors Days Days104171 61.2%  
Net fixed assets Rs m37,63955,432 67.9%   
Share capital Rs m894268 333.8%   
"Free" reserves Rs m26,21013,935 188.1%   
Net worth Rs m27,10514,701 184.4%   
Long term debt Rs m16,3779,478 172.8%   
Total assets Rs m81,16873,988 109.7%  
Interest coverage x2.8-0.4 -774.9%   
Debt to equity ratio x0.60.6 93.7%  
Sales to assets ratio x0.40.1 442.2%   
Return on assets %5.90.5 1,173.3%  
Return on equity %9.2-27.3 -33.9%  
Return on capital %12.1-6.4 -187.5%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m13,4651,860 724.0%   
Fx outflow Rs m4,07625 16,374.8%   
Net fx Rs m9,3891,835 511.7%   
CASH FLOW
From Operations Rs m2,8811,719 167.6%  
From Investments Rs m-7,051-3,148 224.0%  
From Financial Activity Rs m3,3821,426 237.2%  
Net Cashflow Rs m-788-3 23,163.5%  

Share Holding

Indian Promoters % 27.7 33.9 81.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.0 -  
FIIs % 8.6 9.9 86.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 25.9 39.3 65.9%  
Shareholders   56,241 21,482 261.8%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SUN PHARMA  

Compare STRIDES SHASUN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade in Red, Oil on the Boil, and Top Stocks in Action(Pre-Open)

The BSE Sensex closed lower by 53 points to end the day at 36,305. While the broader NSE Nifty ended the day down by 136 points to end at 10,975.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (4QFY18); Net Profit Down 99.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STRIDES SHASUN LTD has posted a net profit of Rs 8 m (down 99.2% YoY). Sales on the other hand came in at Rs 7 bn (down 25.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Sep 24, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD - J.B.CHEMICALS COMPARISON

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS